phrykt

Regeneron Pharmaceuticals (REGN) debt: $2B

Regeneron Pharmaceuticals had $2B of long-term debt on Dec 31, 2025, including the part due within a year, up 0.1% from $2B a year earlier.

From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page

Regeneron Pharmaceuticals debt by year

$2B2021$2B2022$2B2023$2B2024$2B2025

#647 of 2,129 US companies by debt · See the full ranking

Year endedDebtChange
Dec 31, 2025$2B+0%
Dec 31, 2024$2B+0%
Dec 31, 2023$2B+0%
Dec 31, 2022$2B+0%
Dec 31, 2021$2B–

Debt of similar companies

Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest debt. Each name opens the same page for that company.

CompanyDebt, latest yearYear ended
Elanco Animal Health$3.8BDec 31, 2025
PERRIGO$3.6BDec 31, 2025
Amneal Pharmaceuticals$2.6BDec 31, 2025
BridgeBio Pharma$2BDec 31, 2025
Regeneron Pharmaceuticals$2BDec 31, 2025
Ionis Pharmaceuticals$1.8BDec 31, 2025
Prestige Consumer Healthcare$1BDec 31, 2025

Questions and answers

What is Regeneron Pharmaceuticals's debt?

Regeneron Pharmaceuticals had $2B of long-term debt on Dec 31, 2025, including the part due within a year, up 0.1% from $2B a year earlier.

Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology